SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Authors: Willett, B.J., Mantzouratou, A., Buchan, S.L. et al.

Journal: Nature Microbiology

Volume: 7

Issue: 8

Pages: 1161-1179

eISSN: 2058-5276

DOI: 10.1038/s41564-022-01143-7

Abstract:

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.

https://eprints.bournemouth.ac.uk/37255/

Source: Scopus

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Authors: Willett, B.J. et al.

Journal: Nat Microbiol

Volume: 7

Issue: 8

Pages: 1161-1179

eISSN: 2058-5276

DOI: 10.1038/s41564-022-01143-7

Abstract:

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.

https://eprints.bournemouth.ac.uk/37255/

Source: PubMed

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Authors: Willett, B.J. et al.

Journal: NATURE MICROBIOLOGY

Volume: 7

Issue: 8

Pages: 1161-+

ISSN: 2058-5276

DOI: 10.1038/s41564-022-01143-7

https://eprints.bournemouth.ac.uk/37255/

Source: Web of Science (Lite)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.

Authors: Willett, B.J. et al.

Journal: Nature microbiology

Volume: 7

Issue: 8

Pages: 1161-1179

eISSN: 2058-5276

ISSN: 2058-5276

DOI: 10.1038/s41564-022-01143-7

Abstract:

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.

https://eprints.bournemouth.ac.uk/37255/

Source: Europe PubMed Central

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Authors: Willett, B.J. et al.

Journal: Nature Microbiology

Volume: 7

Pages: 1161-1179

ISSN: 2058-5276

Abstract:

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.

https://eprints.bournemouth.ac.uk/37255/

Source: BURO EPrints